内臓痛の世界市場レポート 2025年

内臓痛市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.9％で187億1,000万米ドルに成長します。予測期間の成長は、疼痛管理における技術革新、非侵襲的治療オプションに対する需要の高まり、新興市場と未開拓機会、個別化医療アプローチ、デジタルヘルスソリューションの統合などに起因すると考えられます。予測期間における主な動向としては、複数の手法を用いた疼痛管理へのシフト、代替療法の重視の高まり、特定の疼痛タイプに対する標的療法の台頭、疼痛管理における遠隔医療の役割の増大、疼痛評価における人工知能の統合などが挙げられます。

鎮痛薬に対する需要の高まりが、今後の内臓痛市場の拡大を牽引すると予想されます。鎮痛薬は、痛み信号に対する脳の知覚を軽減または遮断することで痛みを和らげる薬です。これらの薬剤は、神経系に作用して内臓からの疼痛信号を調節することで、内臓痛の管理に役立っています。例えば、2024年4月、英国の週刊医学雑誌New England Journal of Medicineは、2023年12月までに53,600人以上の臨床医がブプレノルフィンを処方しており、2022年12月と比較して11,500人の処方が増加していると報告しています。このように、鎮痛薬に対する需要の高まりが内臓痛市場の成長を後押ししています。

内臓痛市場の有力企業は、NHE3阻害剤などの革新的製品の開発に専念し、消費者に信頼できるソリューションを提供しています。NHE3阻害剤は、消化管内のナトリウム・プロトン交換体サブタイプ3（NHE3）を阻害することで機能する医薬品の一群を構成します。例えば、2022年4月、米国のバイオ医薬品会社であるアーデリクスは、IBSRELAと呼ばれるNHE3阻害薬を発表しました。この画期的な治療薬は、便秘を伴う過敏性腸症候群（IBS-C）の成人を対象とし、小腸と大腸のナトリウム-水素交換体3（NHE3）に作用します。前臨床試験において、内臓知覚過敏と腸管透過性を緩和することにより腹痛を軽減する効果が実証されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界内臓痛PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の内臓痛市場：成長率分析
• 世界の内臓痛市場の実績：規模と成長, 2019-2024
• 世界の内臓痛市場の予測：規模と成長, 2024-2029, 2034F
• 世界内臓痛総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の内臓痛市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルシウムチャネル遮断薬
• 非ステロイド性抗炎症薬（NSAID）
• その他の薬物クラス
• 世界の内臓痛市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 間質性膀胱炎
• クローン病
• 過敏性腸症候群
• 慢性前立腺炎
• その他の適応症
• 世界の内臓痛市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の内臓痛市場カルシウムチャネル遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジヒドロピリジン
• 非ジヒドロピリジン
• 世界の内臓痛市場非ステロイド性抗炎症薬（NSAID）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的 COX-2阻害剤
• 非選択的NSAID
• 世界の内臓痛市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オピオイド
• 三環系抗うつ薬（TCA）
• セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）

第7章 地域別・国別分析

• 世界の内臓痛市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の内臓痛市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 内臓痛市場：競合情勢
• 内臓痛市場：企業プロファイル
  • Walgreens Boots Alliance Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AbbVie Inc.
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company PLC
• Dr. Reddy's Laboratories Ltd.
• Endo International PLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 内臓痛市場2029：新たな機会を提供する国
• 内臓痛市場2029：新たな機会を提供するセグメント
• 内臓痛市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Visceral pain originates from internal organs such as the stomach, bladder, uterus, or rectum and can stem from factors such as inflammation, menstrual cramps, organ swelling, blockages, reduced blood flow, or tumors, particularly in the pelvis or abdomen, often accompanied by symptoms such as nausea, sweating, or increased heart rate.

The principal drug classes for treating visceral pain include calcium channel blockers (CCBs), nonsteroidal anti-inflammatories (NSAIDs), and others. CCBs regulate calcium ion movement into heart and blood vessel cells, with indications spanning interstitial cystitis, Crohn's disease, irritable bowel syndrome, chronic prostatitis, and more. These medications are employed across various end-user settings including hospitals, homecare, specialty clinics, among others.

The visceral pain market research report is one of a series of new reports from The Business Research Company that provides visceral pain market statistics, including visceral pain industry global market size, regional shares, competitors with a visceral pain market share, detailed visceral pain market segments, market trends, and opportunities, and any further data you may need to thrive in the visceral pain industry. This visceral pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The visceral pain market size has grown strongly in recent years. It will grow from $13.84 billion in 2024 to $14.87 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, increased incidence of chronic diseases, advances in medical research, expansion of healthcare infrastructure, rising awareness and diagnosis rates.

The visceral pain market size is expected to see strong growth in the next few years. It will grow to $18.71 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to technological innovations in pain management, growing demand for non-invasive treatment options, emerging markets and untapped opportunities, personalized medicine approaches, integration of digital health solutions. Major trends in the forecast period include shift towards multimodal pain management, increasing emphasis on alternative therapies, rise of targeted therapies for specific pain types, growing role of telemedicine in pain management, integration of artificial intelligence in pain assessment.

The growing demand for analgesics is anticipated to drive the expansion of the visceral pain market in the future. Analgesics are medications that relieve pain by reducing or blocking the brain's perception of pain signals. These medications help manage visceral pain by acting on the nervous system to modulate pain signals from internal organs. For example, in April 2024, the New England Journal of Medicine, a UK-based weekly medical journal, reported that over 53,600 clinicians were prescribing buprenorphine by December 2023, marking an increase of 11,500 prescribers compared to December 2022. Thus, the rising demand for analgesics is fueling the growth of the visceral pain market.

Prominent companies in the visceral pain market are dedicated to developing innovative products such as NHE3 Inhibitors to offer dependable solutions to consumers. NHE3 inhibitors constitute a class of medications that function by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gastrointestinal tract. For example, in April 2022, Ardelyx, a US-based biopharmaceutical firm, introduced an NHE3 Inhibitor medication called IBSRELA. This groundbreaking treatment targets adults with irritable bowel syndrome with constipation (IBS-C), acting on the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. Preclinical studies have demonstrated its efficacy in reducing abdominal pain by alleviating visceral hypersensitivity and intestinal permeability.

In April 2023, Marksans Pharma, a pharmaceutical company based in India, acquired Teva Pharmaceuticals' manufacturing facility in India for an undisclosed amount. This acquisition provides Marksans with a 47,597-square-meter facility, allowing it to double its production capacity in India from 8 billion units per year. The increased capacity will facilitate the production of tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceuticals is an Israel-based company that provides treatments for visceral pain.

Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Endo International PLC, Grunenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.

North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the visceral pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The visceral pain market consists of sales of opioids, anticonvulsants, gabapentin, and pregabalin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Visceral Pain Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on visceral pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for visceral pain ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The visceral pain market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Calcium Channel Blockers; Nonsteroidal Anti-Inflammatory (NSAID); Other Drug Classes
• 2) By Indications: Interstitial Cystitis; Crohn's; Irritable Bowel; Chronic Prostatitis; Other Indications
• 3) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
• 2) By Nonsteroidal Anti-Inflammatory Drugs (NSAID): Selective COX-2 Inhibitors; Non-Selective NSAIDs
• 3) By Other Drug Classes: Opioids; Tricyclic Antidepressants (TCAs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Companies Mentioned: Walgreens Boots Alliance Inc.; Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co.Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Visceral Pain Market Characteristics

3. Visceral Pain Market Trends And Strategies

4. Visceral Pain Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Visceral Pain Growth Analysis And Strategic Analysis Framework

• 5.1. Global Visceral Pain PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Visceral Pain Market Growth Rate Analysis
• 5.4. Global Visceral Pain Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Visceral Pain Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Visceral Pain Total Addressable Market (TAM)

6. Visceral Pain Market Segmentation

• 6.1. Global Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Channel Blockers
• Nonsteroidal Anti-Inflammatory (NSAID)
• Other Drug Classes
• 6.2. Global Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interstitial Cystitis
• Crohn's
• Irritable Bowel
• Chronic Prostatitis
• Other Indications
• 6.3. Global Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.4. Global Visceral Pain Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dihydropyridines
• Non-Dihydropyridines
• 6.5. Global Visceral Pain Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAID), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective COX-2 Inhibitors
• Non-Selective NSAIDs
• 6.6. Global Visceral Pain Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Opioids
• Tricyclic Antidepressants (TCAs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

7. Visceral Pain Market Regional And Country Analysis

• 7.1. Global Visceral Pain Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Visceral Pain Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Visceral Pain Market

• 8.1. Asia-Pacific Visceral Pain Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Visceral Pain Market

• 9.1. China Visceral Pain Market Overview
• 9.2. China Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Visceral Pain Market

• 10.1. India Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Visceral Pain Market

• 11.1. Japan Visceral Pain Market Overview
• 11.2. Japan Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Visceral Pain Market

• 12.1. Australia Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Visceral Pain Market

• 13.1. Indonesia Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Visceral Pain Market

• 14.1. South Korea Visceral Pain Market Overview
• 14.2. South Korea Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Visceral Pain Market

• 15.1. Western Europe Visceral Pain Market Overview
• 15.2. Western Europe Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Visceral Pain Market

• 16.1. UK Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Visceral Pain Market

• 17.1. Germany Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Visceral Pain Market

• 18.1. France Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Visceral Pain Market

• 19.1. Italy Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Visceral Pain Market

• 20.1. Spain Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Visceral Pain Market

• 21.1. Eastern Europe Visceral Pain Market Overview
• 21.2. Eastern Europe Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Visceral Pain Market

• 22.1. Russia Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Visceral Pain Market

• 23.1. North America Visceral Pain Market Overview
• 23.2. North America Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Visceral Pain Market

• 24.1. USA Visceral Pain Market Overview
• 24.2. USA Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Visceral Pain Market

• 25.1. Canada Visceral Pain Market Overview
• 25.2. Canada Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Visceral Pain Market

• 26.1. South America Visceral Pain Market Overview
• 26.2. South America Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Visceral Pain Market

• 27.1. Brazil Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Visceral Pain Market

• 28.1. Middle East Visceral Pain Market Overview
• 28.2. Middle East Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Visceral Pain Market

• 29.1. Africa Visceral Pain Market Overview
• 29.2. Africa Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Visceral Pain Market Competitive Landscape And Company Profiles

• 30.1. Visceral Pain Market Competitive Landscape
• 30.2. Visceral Pain Market Company Profiles
  • 30.2.1. Walgreens Boots Alliance Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Visceral Pain Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Novartis AG
• 31.3. Sanofi SA
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca PLC
• 31.6. GlaxoSmithKline PLC
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Mylan N.V.
• 31.11. Bausch Health Companies Inc.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Perrigo Company PLC
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Endo International PLC

32. Global Visceral Pain Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Visceral Pain Market

34. Recent Developments In The Visceral Pain Market

35. Visceral Pain Market High Potential Countries, Segments and Strategies

• 35.1 Visceral Pain Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Visceral Pain Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Visceral Pain Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer